Osteosarcoma is a malignant bone tumor predominantly affecting adolescents and young adults. Recent cancer research focuses on understanding its genetic and molecular underpinnings to develop targeted therapies. Advances in genomics have identified key mutations and pathways, such as the RB1 and TP53 genes, involved in tumor development. Immunotherapy, particularly the use of immune checkpoint inhibitors, is being explored to enhance the body's immune response against osteosarcoma cells. Additionally, researchers are investigating the tumor microenvironment to identify new therapeutic targets. Despite challenges, these efforts aim to improve prognosis and survival rates for osteosarcoma patients through precision medicine and novel treatment strategies.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China